** Shares of vaccine maker Moderna MRNA.O gain 1.9% to $43.18 premarket
** Co has been awarded tender to supply its mRNA COVID-19 vaccine in the European Union, Norway and North Macedonia, allowing 17 countries to access the vaccine for up to four years
** Tender comes after MRNA cut its 2025 sales forecast by $1 bln earlier this month, partially due to weak demand for its COVID-19 vaccines
** The trim brought co's FY25 revenue forecast below analysts' estimates and sent shares down nearly 17% on Jan. 13
** Seven of 26 brokerages covering stock rate it "buy", 15 rate "hold" and four rate "sell" or lower; median PT is $57 - LSEG data
** MRNA stock more than halved in 2024
(Reporting by Sanchayaita Roy in Bengaluru)
((Sanchayaita.roy@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。